O	0	7	Quality
O	8	10	of
O	11	15	life
O	16	18	in
O	19	22	MAP
O	22	23	.
O	23	24	3
O	25	26	(
O	26	33	Mammary
O	34	44	Prevention
O	45	46	3
O	46	47	)
O	47	48	:
O	49	50	a
O	51	61	randomized
O	61	62	,
O	63	70	placebo
O	70	71	-
O	71	81	controlled
O	82	87	trial
O	88	98	evaluating
B-intervention	99	109	exemestane
O	110	113	for
O	114	124	prevention
O	125	127	of
O	128	134	breast
O	135	141	cancer
O	141	142	.

O	143	153	Exemestane
O	153	154	,
O	155	156	a
O	157	166	steroidal
O	167	176	aromatase
O	177	186	inhibitor
O	186	187	,
B-outcome	188	195	reduced
I-outcome	196	204	invasive
I-outcome	205	211	breast
I-outcome	212	218	cancer
I-outcome	219	228	incidence
O	229	231	by
O	232	234	65
O	234	235	%
O	236	241	among
B-total-participants	242	243	4
I-total-participants	243	244	,
I-total-participants	244	247	560
O	248	262	postmenopausal
O	263	268	women
O	269	277	randomly
O	278	286	assigned
O	287	289	to
O	290	300	exemestane
O	301	302	(
O	302	304	25
O	305	307	mg
O	308	311	per
O	312	315	day
O	315	316	)
O	317	325	compared
O	326	330	with
B-control	331	338	placebo
O	339	341	in
O	342	345	the
O	346	354	National
O	355	361	Cancer
O	362	371	Institute
O	372	374	of
B-location	375	381	Canada
O	382	383	(
O	383	387	NCIC
O	387	388	)
O	389	397	Clinical
O	398	404	Trials
O	405	410	Group
O	411	414	MAP
O	414	415	.
O	415	416	3
O	417	418	(
O	418	425	Mammary
O	426	436	Prevention
O	437	438	3
O	438	439	)
O	440	445	trial
O	445	446	,
O	447	450	but
O	451	458	effects
O	459	461	on
O	462	469	quality
O	470	472	of
O	473	477	life
O	478	479	(
O	479	482	QOL
O	482	483	)
O	484	488	were
O	489	492	not
O	493	498	fully
O	499	508	described
O	508	509	.

O	510	519	Menopause
O	519	520	-
O	520	528	specific
O	529	532	and
O	533	539	health
O	539	540	-
O	540	547	related
O	548	551	QOL
O	552	556	were
O	557	565	assessed
O	566	568	by
O	569	574	using
O	575	578	the
O	579	583	four
O	584	593	Menopause
O	593	594	-
O	594	602	Specific
O	603	610	Quality
O	611	613	of
O	614	618	Life
O	619	632	Questionnaire
O	633	634	(
O	634	640	MENQOL
O	640	641	)
O	642	649	domains
O	650	653	and
O	654	657	the
O	658	663	eight
O	664	671	Medical
O	672	680	Outcomes
O	681	686	Study
O	687	692	Short
O	693	697	Form
O	698	704	Health
O	705	711	Survey
O	712	713	(
O	713	715	SF
O	715	716	-
O	716	718	36
O	718	719	)
O	720	726	scales
O	727	729	at
O	730	738	baseline
O	738	739	,
O	740	741	6
O	742	748	months
O	748	749	,
O	750	753	and
O	754	760	yearly
O	761	771	thereafter
O	771	772	.

B-outcome	773	779	MENQOL
I-outcome	780	793	questionnaire
I-outcome	794	804	completion
O	805	808	was
O	809	813	high
O	814	815	(
O	815	817	88
O	817	818	%
O	819	821	to
O	822	824	98
O	824	825	%
O	825	826	)
O	827	829	in
O	830	834	both
O	835	841	groups
O	842	844	at
O	845	849	each
O	850	856	follow
O	856	857	-
O	857	859	up
O	860	865	visit
O	865	866	.

B-outcome	867	873	Change
I-outcome	874	880	scores
I-outcome	881	884	for
I-outcome	885	889	each
I-outcome	890	896	MENQOL
I-outcome	897	900	and
I-outcome	901	903	SF
I-outcome	903	904	-
I-outcome	904	906	36
I-outcome	907	912	scale
O	912	913	,
O	914	924	calculated
O	925	927	at
O	928	932	each
O	933	943	assessment
O	944	948	time
O	949	957	relative
O	958	960	to
O	961	969	baseline
O	969	970	,
O	971	975	were
O	976	984	compared
O	985	987	by
O	988	993	using
O	994	997	the
O	998	1006	Wilcoxon
O	1007	1011	rank
O	1011	1012	-
O	1012	1015	sum
O	1016	1020	test
O	1020	1021	.

O	1022	1032	Clinically
O	1033	1042	important
O	1043	1051	worsened
O	1052	1055	QOL
O	1056	1059	was
O	1060	1067	defined
O	1068	1070	as
O	1071	1072	a
O	1073	1079	MENQOL
O	1080	1086	change
O	1087	1092	score
O	1093	1101	increase
O	1102	1104	of
O	1105	1109	more
O	1110	1114	than
O	1115	1116	0
O	1116	1117	.
O	1117	1118	5
O	1119	1120	(
O	1120	1122	of
O	1123	1124	8
O	1124	1125	)
O	1126	1132	points
O	1133	1136	and
O	1137	1139	an
O	1140	1142	SF
O	1142	1143	-
O	1143	1145	36
O	1146	1152	change
O	1153	1158	score
O	1159	1167	decrease
O	1168	1170	of
O	1171	1175	more
O	1176	1180	than
O	1181	1182	5
O	1183	1184	(
O	1184	1186	of
O	1187	1190	100
O	1190	1191	)
O	1192	1198	points
O	1199	1203	from
O	1204	1212	baseline
O	1212	1213	.

O	1214	1224	Exemestane
O	1225	1228	had
O	1229	1234	small
O	1235	1243	negative
O	1244	1251	effects
O	1252	1254	on
B-outcome	1255	1260	women
I-outcome	1260	1261	'
I-outcome	1261	1262	s
I-outcome	1263	1267	self
I-outcome	1267	1268	-
I-outcome	1268	1276	reported
I-outcome	1277	1286	vasomotor
I-outcome	1287	1295	symptoms
O	1295	1296	,
B-outcome	1297	1303	sexual
I-outcome	1304	1312	symptoms
O	1312	1313	,
O	1314	1317	and
B-outcome	1318	1322	pain
O	1322	1323	,
O	1324	1329	which
O	1330	1338	occurred
O	1339	1345	mainly
O	1346	1348	in
O	1349	1352	the
O	1353	1358	first
O	1359	1360	6
O	1361	1367	months
O	1368	1370	to
O	1371	1372	2
O	1373	1378	years
O	1379	1384	after
O	1385	1391	random
O	1392	1402	assignment
O	1402	1403	.

O	1404	1411	However
O	1411	1412	,
O	1413	1418	these
O	1419	1426	changes
O	1427	1438	represented
O	1439	1443	only
O	1444	1445	a
O	1446	1451	small
O	1452	1458	excess
O	1459	1465	number
O	1466	1468	of
O	1469	1474	women
O	1475	1480	being
O	1481	1486	given
O	1487	1497	exemestane
O	1498	1502	with
O	1503	1513	clinically
O	1514	1523	important
B-outcome	1524	1533	worsening
I-outcome	1534	1536	of
I-outcome	1537	1540	QOL
O	1541	1543	at
O	1544	1547	one
O	1548	1552	time
O	1553	1555	or
O	1556	1563	another
O	1563	1564	;
O	1565	1577	specifically
O	1577	1578	,
O	1579	1580	8
O	1580	1581	%
O	1582	1586	more
O	1587	1589	in
O	1590	1593	the
B-outcome	1594	1603	vasomotor
I-outcome	1604	1610	domain
O	1611	1614	and
O	1615	1616	4
O	1616	1617	%
O	1618	1622	more
O	1623	1627	each
O	1628	1630	in
O	1631	1634	the
B-outcome	1635	1641	sexual
I-outcome	1642	1648	domain
I-outcome	1649	1652	and
I-outcome	1653	1656	for
I-outcome	1657	1661	pain
O	1661	1662	.

O	1663	1665	No
O	1666	1671	other
O	1672	1679	between
O	1679	1680	-
O	1680	1685	group
O	1686	1697	differences
O	1698	1702	were
O	1703	1711	observed
O	1711	1712	.

O	1713	1720	Overall
O	1720	1721	,
O	1722	1730	slightly
O	1731	1735	more
O	1736	1741	women
O	1742	1744	in
O	1745	1748	the
O	1749	1759	exemestane
O	1760	1763	arm
O	1764	1765	(
B-iv-bin-percent	1765	1767	32
I-iv-bin-percent	1767	1768	%
O	1768	1769	)
O	1770	1774	than
O	1775	1777	in
O	1778	1781	the
O	1782	1789	placebo
O	1790	1793	arm
O	1794	1795	(
B-cv-bin-percent	1795	1797	28
I-cv-bin-percent	1797	1798	%
O	1798	1799	)
B-outcome	1800	1812	discontinued
O	1813	1821	assigned
O	1822	1831	treatment
O	1831	1832	.

O	1833	1843	Exemestane
O	1844	1849	given
O	1850	1853	for
O	1854	1864	prevention
O	1865	1868	has
O	1869	1876	limited
O	1877	1885	negative
O	1886	1892	impact
O	1893	1895	on
O	1896	1905	menopause
O	1905	1906	-
O	1906	1914	specific
O	1915	1918	and
O	1919	1925	health
O	1925	1926	-
O	1926	1933	related
O	1934	1937	QOL
O	1938	1940	in
O	1941	1948	healthy
O	1949	1963	postmenopausal
O	1964	1969	women
O	1970	1972	at
O	1973	1977	risk
O	1978	1981	for
O	1982	1988	breast
O	1989	1995	cancer
O	1995	1996	.
